A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-).
Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 03 Dec 2012
At a glance
- Drugs AC 1204 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms ALERT
- 03 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Jun 2011 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 08 Jun 2011 Planned initiation date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.